3-(3'-bromopropyl)indene | 10409-13-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 3-(3'-bromopropyl)indene
• 英文别名: 3-(3-bromopropyl)-1H-indene；(3-bromopropyl)indene；3-(3-bromo-propyl)-indene；3-(3-Brom-propyl)-inden；3-(3-bromopropyl)indene；1H-Indene, 3-(3-bromopropyl)-
• CAS: 10409-13-9
• 化学式: C₁₂H₁₃Br
• 分子量: 237.139
• InChiKey: AWNRGBYUHUSASE-UHFFFAOYSA-N

物化性质

• 沸点：
  140 °C(Press: 0.8 Torr)
• 密度：
  1.339±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-(3'-bromopropyl)indene 在 盐酸 、 乙醚 、 乙醇 、 氰化钠 、 zinc(II) chloride 作用下， 生成 1-甲基芴
  参考文献：
  名称：

  February asthma outbreaks in NSW: a case control study

  摘要：

  Objectives: To investigate individual factors associated with an asthma outbreak among children aged one to 14 years in Sydney in February 1999. Methods: A case control study was undertaken with cases (n=92) defined as all children admitted to Sydney Children's Hospital for asthma in February 1999. Unmatched controls (n=76) were all children admitted for asthma in the previous three months. We obtained information by a structured telephone survey of parents. Logistic regression analyses were used to determine odds ratios for risk factors for hospital admission. Results: Mean age for hospital admission of 4.7 years for cases and 4.4 years for controls. The presence of one or more siblings reduced the risk of admission during an asthma outbreak (OR=0.59, 95% Cl 0.37 to 0.93). Children with older siblings aged 10 to 14 years were also less likely to be admitted (OR=0.3, 95% Cl 0.12 to 0.74). An age effect was observed. Other demographic, clinical and environmental characteristics, including smoking, were not associated with admission during the outbreak. Conclusions: The main findings of this study are the protective effect of siblings and an age-dependent effect in risk of hospital admission during an asthma outbreak. These findings are consistent with an infective cause of the outbreak. Implications: Children without siblings, particularly older siblings, appear to be at highest risk of hospital admission during an asthma outbreak. Environmental and other factors need to be examined to further explain the episodicity of such outbreaks and to determine means of predicting and preventing future episodes.

  DOI：

  10.1111/j.1467-842x.2001.tb00315.x
• 作为产物：
  描述：

  3-inden-3-yl-propionic acid ethyl ester 在 lithium aluminium tetrahydride 、 乙醚 、 三溴化磷 、 苯 作用下， 生成 3-(3'-bromopropyl)indene
  参考文献：
  名称：

  February asthma outbreaks in NSW: a case control study

  摘要：

  Objectives: To investigate individual factors associated with an asthma outbreak among children aged one to 14 years in Sydney in February 1999. Methods: A case control study was undertaken with cases (n=92) defined as all children admitted to Sydney Children's Hospital for asthma in February 1999. Unmatched controls (n=76) were all children admitted for asthma in the previous three months. We obtained information by a structured telephone survey of parents. Logistic regression analyses were used to determine odds ratios for risk factors for hospital admission. Results: Mean age for hospital admission of 4.7 years for cases and 4.4 years for controls. The presence of one or more siblings reduced the risk of admission during an asthma outbreak (OR=0.59, 95% Cl 0.37 to 0.93). Children with older siblings aged 10 to 14 years were also less likely to be admitted (OR=0.3, 95% Cl 0.12 to 0.74). An age effect was observed. Other demographic, clinical and environmental characteristics, including smoking, were not associated with admission during the outbreak. Conclusions: The main findings of this study are the protective effect of siblings and an age-dependent effect in risk of hospital admission during an asthma outbreak. These findings are consistent with an infective cause of the outbreak. Implications: Children without siblings, particularly older siblings, appear to be at highest risk of hospital admission during an asthma outbreak. Environmental and other factors need to be examined to further explain the episodicity of such outbreaks and to determine means of predicting and preventing future episodes.

  DOI：

  10.1111/j.1467-842x.2001.tb00315.x

文献信息

• Pharmaceutical compositions and methods of treating hypertension
  申请人：John Wyeth & Brother Limited

  公开号：US04029801A1

  公开（公告）日：1977-06-14

  Pharmaceutical compositions containing a group of heterocyclic compounds and their use in treatment of disorders and diseases of the cardiovascular system and/or in the treatment of superficial and deep allergic phenomena is described. These compounds used in the composition and/or methods are piperidine compounds linked by the nitrogen atom to a substituted or unsubstituted cycloalkyl, aryl or heterocyclic radical through the intermediary of a group selected from a lower-alkylene radical, a monoketo lower-alkylene radical or a hydroxy-lower-alkylene radical, or a bivalent radical of the formula --NH.CO.(CH.sub.2).sub.n -- where n is 1, 2 or 3, ##STR1## or --0-(lower-alkylene)--. The piperidine ring is further substituted by an acylamino residue.

  本发明描述了含有杂环化合物组的药物组合物及其在治疗心血管系统疾病和/或治疗浅表和深层过敏现象中的应用。这些组合物和/或方法中使用的化合物是哌啶化合物，通过氮原子与取代或未取代的环烷基、芳基或杂环基团相连，中间通过一个选自低级烷叉基、单酮低级烷叉基或羟基低级烷叉基的基团，或一个二价基团，其公式为--NH.CO.(CH.sub.2).sub.n --，其中n为1、2或3，##STR1##或--O-(低级烷叉基)--。哌啶环进一步被酰胺基残基取代。
• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE LA MYÉLOPEROXYDASE À BASE DE TRIAZOLOPYRIDINES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017160632A1

  公开（公告）日：2017-09-21

  The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

  本发明提供了式（I）的化合物。其中A和Z如规范中所定义，并包括任何这类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂，可能对动脉粥样硬化、心力衰竭、慢性阻塞性肺病（COPD）及相关疾病的治疗和/或预防有用。
• Fluorenylhydroxamic acids isomeric with the carcinogens N-fluoren-2-ylacetohydroxamic acid. Part I. Synthesis of N-fluoren-1-yl-, N-fluoren-3-yl-, and N-fluoren-4-ylacetohydroxamic acid
  作者：Yul Yost、H. R. Gutmann

  DOI：10.1039/j39690000345

  日期：——

  Three new fluorenylhydroxamic acids isomeric with the carcinogen N-fluoren-2-ylacetohydroxamic acid have been synthesized by partial catalytic reduction of the corresponding nitrofluorenes, prepared in turn by oxidation of the respective fluorenamines with peroxymaleic acid. A route to N([1-14C]fluoren-1-yl)acetamide and -acetohydroxamic acid by aromatization of the oxime of 3,4-dihydrofluoren-1 (2H)-one

  通过部分催化还原相应的硝基芴，合成了三种与致癌物N-芴-2-基乙酰氧肟酸同分异构的新芴基异羟肟酸，而相应的硝基芴又是用过氧马来酸氧化相应的芴胺而制得的。探索了一种通过Semmler-Wolff重排将3,4-二氢芴-1（2 H）-肟肟化的方法，制得N（[[ 14 C]芴-1-基）乙酰胺和-乙酰氧肟酸的途径。。通过TLC对产物的分析表明，当在有限量的乙酸酐存在下重排该肟时，亚胺为中间体。
• <i>N</i>-[ω-(Tetralin-1-yl)alkyl] Derivatives of 3,3-Dimethylpiperidine Are Highly Potent and Selective σ₁ or σ₂ Ligands
  作者：Francesco Berardi、Sergio Santoro、Roberto Perrone、Vincenzo Tortorella、Stefano Govoni、Laura Lucchi

  DOI：10.1021/jm970692a

  日期：1998.10.1

  089 nM) and selective sigma1 ligand (1340-fold), showing a 10-fold enantioselectivity. Compounds 29 (3, 3-dimethyl-1-[4-(6-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)-n-butyl]piperidine) and 31 (3, 3-dimethyl-1-[5-(1,2,3, 4-tetrahydronaphthalen-1-yl)-n-pentyl]piperidine) were highly potent (IC50 = 0.016 nM and IC50 = 0.008 nM, respectively) and highly selective sigma2 ligands (more than 100000-fold)

  制备了几种3，3-二甲基-N-ω-（四氢萘-1-基）烷基]哌啶衍生物和一些相关化合物。通过放射性配体结合试验研究了它们的亲和力和sigma亚型选择性，用[3H] -SKF 10047标记了sigma1受体，并用[3H] -DTG标记了sigma2受体。许多测试的化合物以纳摩尔或亚纳摩尔IC50值结合sigma1和/或sigma2受体。化合物（+）-22，（+）-3,3-二甲基-1- [3-（5-甲氧基-1,2,3,4-四氢萘-1-基）-正丙基]哌啶是最有效的（IC50 = 0.089 nM）和选择性的sigma1配体（1340倍），显示出10倍的对映选择性。化合物29（3，3-二甲基-1- [4-（6-甲氧基-1,2,3，4-四氢萘-1-基）-正丁基]哌啶）和31（3，3-二甲基-1 -[5-（1,2,3，4-四氢萘-1-基）-正戊基]哌啶）的效力很高（IC50 = 0。
• Indanpentol derivatives
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04053596A1

  公开（公告）日：1977-10-11

  Compounds are provided having the structure ##STR1## wherein n is 1, 2 or 3, m is 0, 1 or 2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be the same or different and can be hydrogen, lower alkyl, halo-lower alkyl, acyl, lower alkoxy-carbonyl ##STR2## amido ##STR3## or lower alkoxyalkylene, X is a straight or branched bivalent aliphatic radical and Y is ##STR4## These compounds are useful in the treatment of hypertension.

  提供具有结构##STR1##的化合物，其中n为1、2或3，m为0、1或2，R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5可以相同也可以不同，可以是氢、低烷基、卤代低烷基、酰基、低烷氧羰基##STR2##氨基##STR3##或低烷氧基烷基，X是直链或支链的双价脂肪族基，Y是##STR4##这些化合物在治疗高血压方面是有用的。